The Filing Desk

Castle Biosciences vs Fulgent Genetics

Castle Biosciences CSTL · Fulgent Genetics FLGT · Health Care Services

Castle Biosciences reported revenue of $344 million in fiscal 2025, about the same as Fulgent Genetics' $323 million in fiscal 2025. Castle Biosciences' revenue grew 3.7% in its latest year, and Fulgent Genetics' grew 13.8%. Castle Biosciences had an operating margin of -12.4%, against -28.2% at Fulgent Genetics. Free cash flow was $28 million at Castle Biosciences and −$124 million at Fulgent Genetics.

Side by side

Castle BiosciencesFulgent Genetics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$344M$323M
Revenue growth3.7%13.8%
Revenue growth a year, last 5 years40.6%−5.2%
Gross margin79.4%40.6%
Operating margin−12.4%−28.2%
Net margin−7.0%−18.8%
Free cash flow$28M−$124M
Free cash flow margin8.2%−38.5%
Return on capital−19.1%−8.7%
Net debt to EBITDA——
Dividends and buybacks$0M$11M
Change in diluted share count−0.9%1.8%
Last close$33.41$24.78
P/E at the last close——
Insider trades, last 12 monthssold $16.6 millionsold $386,628
Piotroski F-score4 of 94 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Castle BiosciencesFulgent Genetics
Operating margin
Percent of revenue
Castle BiosciencesFulgent Genetics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Castle BiosciencesFulgent Genetics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Castle Biosciences and Fulgent Genetics pages.